home / stock / rckt / rckt quote
Last: | $21.32 |
---|---|
Change Percent: | -0.47% |
Open: | $21.55 |
Close: | $21.32 |
High: | $22.1 |
Low: | $20.945 |
Volume: | 544,046 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$21.32 | $21.55 | $21.32 | $22.1 | $20.945 | 544,046 | 05-31-2024 |
$21.45 | $20.97 | $21.45 | $21.46 | $20.69 | 683,734 | 05-30-2024 |
$20.66 | $20.71 | $20.66 | $21.03 | $20.175 | 908,061 | 05-29-2024 |
$20.94 | $21.75 | $20.94 | $21.75 | $20.63 | 1,081,531 | 05-28-2024 |
$21.42 | $21.87 | $21.42 | $22.02 | $21.41 | 584,227 | 05-27-2024 |
$21.42 | $21.87 | $21.42 | $22.02 | $21.41 | 584,227 | 05-24-2024 |
$21.72 | $22.49 | $21.72 | $22.5 | $21.38 | 765,540 | 05-23-2024 |
$22.44 | $22.22 | $22.44 | $22.92 | $22.18 | 676,240 | 05-22-2024 |
$22.33 | $22.65 | $22.33 | $23.05 | $22.21 | 527,713 | 05-21-2024 |
$22.83 | $22.7 | $22.83 | $23.15 | $22.65 | 471,940 | 05-20-2024 |
$22.62 | $23.46 | $22.62 | $23.56 | $22.45 | 564,827 | 05-17-2024 |
$23.4 | $23.7 | $23.4 | $23.7 | $23.16 | 604,224 | 05-16-2024 |
$23.66 | $23.97 | $23.66 | $24.46 | $23.53 | 418,200 | 05-15-2024 |
$23.38 | $23.41 | $23.38 | $24 | $23.36 | 338,523 | 05-14-2024 |
$23.09 | $22.92 | $23.09 | $23.405 | $22.83 | 363,426 | 05-13-2024 |
$22.72 | $23.49 | $22.72 | $23.64 | $22.72 | 401,938 | 05-10-2024 |
$23.33 | $23.05 | $23.33 | $23.9099 | $22.88 | 510,950 | 05-09-2024 |
$22.98 | $23.31 | $22.98 | $23.58 | $22.67 | 595,164 | 05-08-2024 |
$23.36 | $23.38 | $23.36 | $23.38 | $22.27 | 692,507 | 05-07-2024 |
$23.2 | $23.54 | $23.2 | $23.605 | $22.86 | 422,956 | 05-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...
Long-term KRESLADI TM follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplantation (HSCT) from 18 to 45 months with a well-tolerated safety profile in all nine patients with severe LAD-I Previously disclosed results from the global R...
Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first half of 2024 Continued preparations to launch LV portfolio beginning with KRESLADI™ (marnetegragene autotemcel) for severe LAD-I; PDUFA date of Ju...